CD8A and cancer: Since VLPs and even pentameric structures are able to break T cell tolerance and since both antigen-specific CD4 and CD8 T cells are required for CMI, heterologous VLP-based vaccines delivering complete antigens or appropriate protein fragments will offer new therapeutic opportunities in the treatment of cancer or chronic infectious disease.